Company: APXIF
Filing Date: 2025-03-31
Form Type: F-4/A
Source: 0001213900-25-026339
Chunk: 353

Company: APx Acquisition Corp. I
Filing Date: 2025-03-31
Form: F-4/A
Chunk 353
---
 and directed to four partner clinical labs in the different cities participating in the project for sample collection and signing an informed consent. In the screening phase, individuals who did not meet the established inclusion or exclusion criteria were excluded from participation. The sample inclusion criteria specified that participants must be adults, either male or female, aged between 18 and 50 years. They were required to undergo a physical examination that revealed no clinically relevant findings. Additionally, participants needed to have non -reactiveserology tests for Hepatitis B Virus surface antigen (HBsAg), antibodies against human immunodeficiency virus (anti -HIV), and Hepatitis C Virus antibodies (anti -HCV). Female volunteers were required to have a negative blood pregnancy test, and all participants needed to be capable of reading, understanding, and signing an informed consent form. The sample exclusion criteria outlined several conditions for disqualification. Participants were excluded if they suffered from gastrointestinal disorders, such as chronic intestinal inflammation, ulcerative colitis, Crohn’s disease, indeterminate colitis, moderate to severe irritable colon syndrome, infectious gastroenteritis, colitis, or gastritis. Chronic or persistent diarrhea of unknown origin, recurrent Clostridium difficile infection, untreated Helicobacter pylori infection, and chronic constipation also constituted grounds for exclusion. Furthermore, individuals who had consumed any antibiotics (oral or intravenous), corticoids (oral, intravenous, intramuscular, nasal, or inhaled), cytokines, drugs stimulating the immune system (such as interleukins), cytotoxic agents (chemotherapy), or large doses of probiotics within the last six months prior to sampling were excluded. Additional exclusion factors included a diagnosis of any disease in the previous six months, chronic use of any type of medication, habitual vegan or vegetarian diets, and a Body Mass Index (BMI) exceeding 29.99, indicating obesity. Following the above criteria, 172 volunteers were accepted for biochemical and metabolome analysis from blood and urine samples, and microbiome analysis from stool samples. These resulted in a total of 516 biological samples processed in the laboratory for biochemical, metabolome, and microbiome data. To enhance analysis accuracy, epidemiological and contextual metadata was collected from each volunteer using a questionnaire for general background information diet, clinical history, gestational history, and medication history was collected. Rewell leverages this comprehensive reference data to provide scientifically precise results, enabling users to manage their long -termhealth. This precision extends to detecting dysbiosis or imbalances in specific microbiome